Çocukluk Çağı Lenfoması Ve Tedavisi

Yıl 2025, Cilt: 1 Sayı: 1, 60 - 73, 17.01.2025

Altay Babacan , Feray Ferda Şenol , Serdar Ümit Sarıcı , Ayça Törel Ergür , Özlem Aytaç

Öz

Lenfoma, lenfoid dokulardan veya organlardan kaynaklanan üçüncü en yaygın çocukluk çağı malignitesidir. Vakaların çoğunda lenfomalar lenf düğümlerinden kaynaklanır. Lenf düğümü dışındaki lenf düğümlerinde kaynaklanan lenfomalar ekstranodal lenfomalar olarak sınıflandırılır. Çocukluk çağı lenfomaları iki ana kategoriye ayrılır: Hodgkin hastalığı ve Hodgkin dışı lenfoma. Hodgkin hastalığı vakalarının büyük çoğunluğu lenf düğümlerinden kaynaklanırken, Hodgkin dışı lenfoma bu yapıların içinden veya dışından da gelişebilir. Hızla büyüyen bu kanser için lenfomanın erken tedavisi son derece önemlidir. Cerrahın, hastalığın klinik semptomlarını tanıyabilmesi ve tanıya hemen dâhil olması zorunludur.

Anahtar Kelimeler

Çocuk, Lenfoma, Tedavi

Etik Beyan

This article does not contain any research involving humans or animals requiring ethical approval.

Childhood Lymphoma and Treatment

Öz

Lymphoma ranks as the third most prevalent childhood cancer, emerging from lymphoid tissues and organs. Most commonly, lymphomas start in the lymph nodes. When lymphomas begin outside the lymph nodes, they're known as extranodal lymphomas. Childhood lymphomas fall into two main groups: Hodgkin's disease and non-Hodgkin's lymphoma. While Hodgkin's disease typically starts in lymph nodes, non-Hodgkin's lymphoma can begin either inside or outside these structures. Quick intervention is essential for this fast-growing cancer. Medical professionals, must recognize the signs quickly and play an active role in diagnosis.

Anahtar Kelimeler

Childhood, Lymphoma, Treatment

Etik Beyan

This article does not contain any research involving humans or animals requiring ethical approval.

Kaynakça

• Hudson MM, Krasin MJ, Kaste SC. Pediatrik Hodgkin lenfomada PET görüntüleme. Pediatrik radyoloji. 2004;34(3):190-198.
• Shukla NN, Trippett TM. Non-Hodgkin’s lymphoma in children and adolescents. Current oncology reports. 2006;8(5):387-394.
• Devesa SS, Fears T. Non-Hodgkin’s lymphoma time trends: United States and international data. Cancer research: 1992;52(19_Supplement):5432s-5440s.
• Eden OB. Oncology and terminal care. Forfar and ArNeil’s: Textbook of Pediatrics. New York: Churchill Livingstone; 1998. p.884-934.
• Al-Samawi AS, Aulaqi SM, Al-Thobhani AK. Childhood lymphomas in Yemen. Saudi Med J. 2009;30(9):1192-1196.
• Anderson JR, Jenkin RD, Wilson JF, Kjeldsberg CR, Sposto R, Chilcote RR, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Childrens Cancer Group. Journal of Clinical Oncology. 1993;11(6):1024-1032.
• Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB. Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. New England Journal of Medicine. 1997;337(18):1259-1266.
• Cairo MS, Krailo MD, Morse M, Hutchinson R J, Harris RE, Kjeldsberg CR, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate (‘Orange’) in children with advanced non-lymphoblastic non-Hodgkin’s lymphoma: a children’s cancer group report. Leukemia. 2002;16(4):594-600.
• Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. British journal of haematology. 2002;117(4):812-820.
• Brugieres L, Deley ML, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe M J, et al. CD30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. The Journal of the American Society of Hematology. 1998;92(10):3591-3598.
• Brugieres L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Annals of Oncology. 2000;11(1):53-58.
• Jaffe ES. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. 2001:185-187.
• Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B,et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86(1):45-53.
• Siebert R, Matthiesen P, Harder S, Zhang Y, Borowski A, Zühlke-Jenisch, et al. Application of interphase fluorescence in situ Hybridization for the detection of the Burkitt translocation t(8;14) (q24;q32) in B-cell lymphomas. Blood. 1998;91(3):984-90.
• Van Krieken JH, Langerak AW, Macintyre EA, Kneba M, Hodges E, Sanz RG, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2007;21(2):201-6.
• Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-30.
• Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ,et al Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431-42.
• Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335-42.
• Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24(3):491-9.
• Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95(2):416-21.
• Bergeron C, Celine S, Pacquement H, Perel Y, Coze C, Gandemer V, et al. Childhood T-cell lymphoblastic lymphoma (TLL) results of the SFOP LMT96 strategy. Pediatr Blood Cancer. 2006;46:867a.
• Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, et al. Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol. 2001;19(7):1935-42.
• Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol. 2007;25(25):3915-22.
• Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;13(6):1368-76.
• Murphy SB, Bowman WP, Abromowitch M, Mirro J, Ochs J, Rivera G, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986;4(12):1732-9.
• Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370-9.
• Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J,et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14(4):1252-61.
• Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-58.
• Gentet JC, Patte C, Quintana E, Bergeron C, Rubie H, Pein F,et al. Demaille MC, Philip T, Raybaud C. Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin's lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol. 1990;8(4):661-5.
• Patte C, Laplanche A, Bertozzi AI, Baruchel A, Frappaz D, Schmitt C, et al. Mechinaud F, Nelken B, Boutard P, Michon J. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol. 2002;20(2):441-8.
• Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol. 2002;13(5):789-95.
• Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-80.
• Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736-43.
• Shanbhag S, Ambinder R.F. Hodgkin lymphoma: A review and update on recent progress. CA: a cancer journal for clinicians, 2018;68(2):116-132.
• Mikhaeel NG, Milgrom SA, Terezakis S, Berthelsen AK, Hodgson D, Eich HT, et al. The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2019;104(3):501-512.
• Appel BE, Chen L, Buxton AB, Hutchison RE, Hodgson DC, Ehrlich PF, et al. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol. 2016;34(20):2372-9.
• Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. Br J Haematol. 2007;138(6):761-8.
• Marks LJ, Pei Q, Bush R, Buxton A, Appel B, Kelly KM, et al. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018;65(12):e27375.
• Mauz-Körholz C, Lange T, Hasenclever D, Burkhardt B, Feller AC, Dörffel W, et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr. 2015; 227(6-7):314-21.
• Fanale MA, Cheah CY, Rich A, Medeiros LJ, Lai CM, Oki Y, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017; 130(4):472-477.
• Culić S, Armanda V, Kuljis D, Kuzmic I, Pranic-Kragic A, Jankovic S. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl. Pediatr Hematol Oncol. 2006;23(8):661-6.
• Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911.
• Plana JC, Galderisi M, Barac A, Ewer MS, Ky B,et al. S Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-39.
• Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73(6):881-95.
• Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-9.